Literature DB >> 7488396

Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes.

G Wozel1, B Lehmann.   

Abstract

Dapsone (4,4'-diaminodiphenylsulfone) is effective in treating inflammatory skin diseases. Several lines of evidence suggest that the anti-inflammatory properties of this sulfone are partially due to modulation of functions of polymorphonuclear leukocytes (PMN). The goal of the present investigation is therefore to ascertain possible inhibitory effects of dapsone upon human 5-lipoxygenase (5-LOX) pathway. PMN of healthy donors were pretreated with dapsone in different concentrations (1.6-100 microM) for 5 min following by adding Ca ionophore A 23187 (10 microM) and subsequent incubation for 10 min. Thereupon the eicosanoids were assessed by reversed-phase high-performance liquid chromatography (RP-HPLC). Dapsone exhibited dose-dependent inhibitory activity showing 50% inhibition at 15 microM for leukotriene B4 (LTB4) with 5 x 10(6) PMN. The IC50 (half maximum inhibition concentration) of dapsone for 5-hydroxyeicosatetraenoic acid (5-HETE) and omega-OH-LTB4 amounted to similar values (5-HETE: 9 microM; omega-OH-LTB4: 11 microM). The inhibition of the conversion of arachidonic acid to several eicosanoids mainly suggests an effect on the 5-LOX enzyme. The comparison of inhibition values between intact PMN and a cell-free system (by sonification) indicates an additional effect of dapsone upon enzymes other than 5-LOX. Since the concentrations used are comparable with therapeutic conditions, dapsone may exert part of its anti-inflammatory effect by prevention of the generation of 5-LOX metabolites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488396     DOI: 10.1159/000211346

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  8 in total

Review 1.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

Review 2.  A comprehensive insight into the anti-inflammatory properties of dapsone.

Authors:  Mina Khalilzadeh; Maryam Shayan; Sina Jourian; Mohammad Rahimi; Mohammad Sheibani; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-20       Impact factor: 3.195

3.  Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.

Authors:  Georg Karpel-Massler; Richard E Kast; Markus D Siegelin; Annika Dwucet; Elisabeth Schneider; Mike-Andrew Westhoff; Christian Rainer Wirtz; Xiao Yun Chen; Marc-Eric Halatsch; Carsten Bolm
Journal:  Neurochem Res       Date:  2017-08-29       Impact factor: 3.996

4.  Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.

Authors:  Matt Morgan; Andrew Cooke; Laura Rogers; Beverley Adams-Huet; David A Khan
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct

Review 5.  The role of inflammation in the pathology of acne.

Authors:  Emil A Tanghetti
Journal:  J Clin Aesthet Dermatol       Date:  2013-09

Review 6.  The Effects of Antibiotics for Helicobacter pylori Eradication or Dapsone on Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.

Authors:  Jun Watanabe; Junya Shimamoto; Kazuhiko Kotani
Journal:  Antibiotics (Basel)       Date:  2021-02-04

7.  High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: new insights into impaired diabetic wound healing.

Authors:  Cheng-Che E Lan; Ching-Shuang Wu; Shu-Mei Huang; I-Hui Wu; Gwo-Shing Chen
Journal:  Diabetes       Date:  2013-02-19       Impact factor: 9.461

8.  Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors:  R E Kast
Journal:  Springerplus       Date:  2015-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.